Table 3.
Dose reduction status due to adverse events during sorafenib treatment by treatment period
2008–2012 period (n = 154) | 2013–2017 period (n = 184) | p value | |
---|---|---|---|
Dose reduction to 400 mg/day | 113 (75.3) | 157 (86.4) | 0.009 |
Re-escalation to 800 mg/day | 34/113 (30.2) | 35/157 (22.0) | 0.341 |
Dose reduction to 200 mg/day | 21 (18.2) | 56 (35.2) | <0.001 |
Re-escalation to 400 mg/day | 15/21 (71.4) | 34/56 (60.7) | 0.691 |
Data are expressed as frequencies (percentage). Modified from Ref. [7].